Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

UPJOHN BROPIRIMINE SHOWS 51% COMPLETE RESPONSE RATE FOR BLADDER CARCINOMA

Executive Summary

UPJOHN BROPIRIMINE SHOWS 51% COMPLETE RESPONSE RATE FOR BLADDER CARCINOMA in a Phase II trial presented by Michael Sarosdy, MD, University of Texas, San Antonio, to the American Society of Clinical Oncology in Dallas May 17. A 3 g dally dose of the oral interferon inducer resulted in complete responses in 20 of 39 evaluable patients with bladder carcinoma in situ.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS024523

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel